These medications work by mimicking the action of naturally occurring GLP-1, a hormone released from the gut after eating
NovoCare , NovoFine , and Ozempic are registered trademarks of Novo Nordisk A/S
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that activates both GIP and GLP-1 receptors, whereas traditional GLP-1 receptor agonists such as semaglutide and liraglutide target only the GLP-1 pathway
Rather than just medication alone, it focuses on sustainable, long-term results through structured education, regular check-ins, and ongoing accountability
Ro offers the following FDA-approved GLP-1 medications: Wegovy (semaglutide): available as a pen and pill (both have cash-pay options) Foundayo (orforglipron): available as a pill (has a cash-pay option) Zepbound (tirzepatide): available as a pen or KwikPens and vials (the latter two have cash-pay options) Ozempic (semaglutide): available as a pen GLP-1s mimic a natural hormone in the body known as glucagon-like peptide-1 (GLP-1)
Additionally, semaglutide slows gastric emptying, which prolongs the sensation of fullness after meals and reduces appetite through effects on appetite centers in the brain